Dr. Adam Greenbaum

Adam B. Greenbaum 313-916-3875 - agreenb1@hfhs.org

Dr. Greenbaum, MD

Adam Greenbaum, MDPHYSICIAN

Henry Ford Hospital

Adam Greenbaum, M.D.Henry Ford Hospital

"For patients who are not candidates for bypass surgery because of either the location of the blockage or surgical risk, there are no other significant treatments for severe PAD other than amputation," says Henry Ford cardiologist Adam Greenbaum, M.D. "This gene therapy could have a significant impact on the quality of life for these patients including preventing the loss of a limb."

Adam Greenbaum MD - Associate Director of the Henry Ford Diagnostic and Interventional Cardiac Catheterization Laboratory.Interventional and research training at Duke University and the Duke Clincial Research Institute.Research focus includes new device technology, pharmacologic therapy during percutaneous intervention, acute coronary syndromes and peripheral vascular disease.

Dr. Adam Greenbaum pioneered our peripheral program in the cath lab at Henry Ford Hospital.
...
They maintain and are responsible for 12 current enrolling trials in collaboration with 6 main investigators: Dr. Mayra Guerrero, Dr. Abdulrahman Arabi, Dr. Aaron Kugelmass, Dr. Henry Kim, Dr. Adam Greenbaum and Dr. Michael Hudson.
...
Adam Greenbaum, MD

• EVENT REGISTRY.A multi-center registry for the evaluation of drug-eluting stents and ischemic events. Primary Investigator: Adam Greenbaum, MD
...
Adam Greenbaum, MD

• CHAMPION PCI.A clinical trial comparing treatment with Cangrelor (an IV anti-platelet agent) to clopidogrel in subjects who require percutaneous intervention.Primary Investigator: Adam Greenbaum, MD

• REVEAL: Erythropoietin for AMI NIH.Randomized, multi-center, double-blind, and placebo-controlled trial of the effects of erythropoietin on infarct size and left ventricular remodeling in survivors of acute myocardial infarction.The primary objective of this study is to determine whether erythropoietin administration affects infarct size, left ventricular remodeling and circulating endothelial progenitor cells in patients with large MIs.The size of the infarction and the dimensions of the heart will be assessed by cardiac magnetic resonance imaging within 2-6 days of the infusion and again approximately 3 months later.Primary Investigator: Adam Greenbaum, MD
...
Adam Greenbaum, MD
...
Various members of the HFHS cath lab contributed their thoughts in response to this question (see also the large quotations from Dr. Kim and Dr. Greenbaum):
...
Adam Greenbaum, MD
...
â€" Adam Greenbaum, MD, Associate Director Cardiac Catheterization Lab

â€" Adam Greenbaum, MD, AssociateDirector Cardiac Catheterization Lab
...
Dr. Adam Greenbaum pioneered our peripheral program in the cath lab at Henry Ford Hospital.
...
They maintain and are responsible for 12 current enrolling trials in collaboration with 6 main investigators: Dr. Mayra Guerrero, Dr. Abdulrahman Arabi, Dr. Aaron Kugelmass, Dr. Henry Kim, Dr. Adam Greenbaum and Dr. Michael Hudson.
...
Adam Greenbaum, MD

EVENT REGISTRY.A multi-center registry for the evaluation of drug-eluting stents and ischemic events.Primary Investigator:Adam Greenbaum, MD
...
Adam Greenbaum, MD

CHAMPION PCI.A clinical trial comparing treatment with Cangrelor (an IV anti-platelet agent) to clopidogrel in subjects who require percutaneous intervention.Primary Investigator:Adam Greenbaum, MD

REVEAL: Erythropoietin for AMI NIH.Randomized, multi-center, double-blind, and placebo-controlled trial of the effects of erythropoietin on infarct size and left ventricular remodeling in survivors of acute myocardial infarction.The primary objective of this study is to determine whether erythropoietin administration affects infarct size, left ventricular remodeling and circulating endothelial progenitor cells in patients with large MIs.The size of the infarction and the dimensions of the heart will be assessed by cardiac magnetic resonance imaging within 2-6 days of the infusion and again approximately 3 months later.Primary Investigator:Adam Greenbaum, MD
...
Adam Greenbaum, MD
...
Various members of the HFHS cath lab contributed their thoughts in response to this question (see also the large quotations from Dr. Kim and Dr. Greenbaum):

In this project, Dr. Adam Greenbaum, associate director, Cardiac Catheterization Laboratory at the Henry Ford Heart and Vascular Institute, and colleagues from nine other institutions analyzed the CRUSADE database for outcomes of patients admitted for high-risk chest pain disorders collectively known as non-ST-segment elevation acute coronary syndromes (NSTE ACS) based on the timing of GP IIb-IIIa inhibitor initiation.

In this project, Dr. Adam Greenbaum, associate director, Cardiac Catheterization Laboratory at the Henry Ford Heart and Vascular Institute, and colleagues from nine other institutions analyzed the CRUSADE database for outcomes of patients admitted for high-risk chest pain disorders collectively known as non-ST-segment elevation acute coronary syndromes (NSTE ACS) based on the timing of GP IIb-IIIa inhibitor initiation.
...
"These data suggest that earlier administration of GP IIb-IIIa inhibitors, prior to angiography, may reduce the risk of death or heart attack," said Dr. Greenbaum.